These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 17890266

  • 41. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D, Smith RJ, Qiu KG, Levy GA, Lilly L, Therapondos G.
    Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
    [Abstract] [Full Text] [Related]

  • 42. Sirolimus in de novo heart transplant recipients with severe renal impairment.
    Vazquez de Prada JA, Vilchez FG, Cobo M, Ruisanchez C, Valls MF, Ruano J, Piñera C, Duran RM.
    Transpl Int; 2006 Mar; 19(3):245-8. PubMed ID: 16441775
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors.
    Cruzado JM.
    Transplant Rev (Orlando); 2008 Jan; 22(1):73-81. PubMed ID: 18631860
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. The future role of target of rapamycin inhibitors in renal transplantation.
    Schwarz C, Oberbauer R.
    Curr Opin Urol; 2002 Mar; 12(2):109-13. PubMed ID: 11859256
    [Abstract] [Full Text] [Related]

  • 48. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
    Watson CJ, Gimson AE, Alexander GJ, Allison ME, Gibbs P, Smith JC, Palmer CR, Bradley JA.
    Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
    [Abstract] [Full Text] [Related]

  • 49. Sirolimus-based immunosuppression: present state of the art.
    Kahan BD.
    J Nephrol; 2004 Dec; 17 Suppl 8():S32-9. PubMed ID: 15599884
    [Abstract] [Full Text] [Related]

  • 50. Leflunomide with low-dose everolimus for treatment of Kaposi's sarcoma in a renal allograft recipient.
    Basu G, Mohapatra A, Manipadam MT, Mani SE, John GT.
    Nephrol Dial Transplant; 2011 Oct; 26(10):3412-5. PubMed ID: 21775763
    [Abstract] [Full Text] [Related]

  • 51. Reviewing the evidence for de novo immunosuppression with sirolimus.
    Flechner SM.
    Transplant Proc; 2008 Dec; 40(10 Suppl):S25-8. PubMed ID: 19100902
    [Abstract] [Full Text] [Related]

  • 52. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction.
    Gustafsson F, Ross HJ, Delgado MS, Bernabeo G, Delgado DH.
    J Heart Lung Transplant; 2007 Oct; 26(10):998-1003. PubMed ID: 17919619
    [Abstract] [Full Text] [Related]

  • 53. [Use of Sirolimus in five pediatric patients undergoing solid organ transplantation].
    Roque E J, Ríos M G, Vignolo A P, Pinochet V C, Schultz M, Humeres A R, Delucchi A, Rius A M, Hepp K J.
    Rev Med Chil; 2008 May; 136(5):631-6. PubMed ID: 18769812
    [Abstract] [Full Text] [Related]

  • 54. mTOR inhibitors: do they help preserve renal function?
    Moro J, Almenar L, Martínez-Dolz L, Agüero J, Rueda J, Arnau MA, Izquierdo M, Cano O, Sánchez-Lázaro I, Salvador A.
    Transplant Proc; 2007 Sep; 39(7):2135-7. PubMed ID: 17889116
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. New advances in antirejection therapy.
    Chan M, Pearson GJ.
    Curr Opin Cardiol; 2007 Mar; 22(2):117-22. PubMed ID: 17284990
    [Abstract] [Full Text] [Related]

  • 58. Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.
    Gaumann A, Schlitt HJ, Geissler EK.
    Transpl Int; 2008 Mar; 21(3):207-17. PubMed ID: 18069922
    [Abstract] [Full Text] [Related]

  • 59. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
    Valantine H.
    J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
    [Abstract] [Full Text] [Related]

  • 60. Sirolimus: its role in nephrology.
    Lee VW, Chapman JR.
    Nephrology (Carlton); 2005 Dec; 10(6):606-14. PubMed ID: 16354246
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.